Objective-To evaluate the safety and feasibility of intramuscular gene transfer using naked plasmid DNA-encoding hepatocyte growth factor (HGF) and to assess its potential therapeutic benefit in patients with critical limb ischemia. Methods and Results-Gene transfer was performed in 22 patients with critical limb ischemia by intramuscular injection of HGF plasmid, either 2 or 4 mg, 2 times. Safety, ankle-brachial index, resting pain on a 10-cm visual analog scale, wound healing, and walking distance were evaluated before treatment and at 2 months after injection. No serious adverse event caused by gene transfer was detected over a follow-up of 6 months. Of particular importance, no peripheral edema, in contrast to that seen after treatment with vascular endothelial growth factor, was observed. In addition, the systemic HGF protein level did not increase during the study. At 2 months after gene transfer, the meanϮSD ankle-brachial index increased from 0.46Ϯ0.08 to 0.59Ϯ0.13 (PϽ0.001), the meanϮSD size of the largest ischemic ulcers decreased from 3.08Ϯ1.54 to 2.32Ϯ1.88 cm (Pϭ0.007), and the meanϮSD visual analog scale score decreased from 5.92Ϯ1.67 to 3.04Ϯ2.50 cm (Pϭ0.001). An increase in ankle-brachial index by Ͼ0.1, a reduction in ulcer size by Ͼ25%, and a reduction in visual analog scale score by Ͼ2 cm at 2 months after gene transfer were observed in 11 (64.7%) of 17 limbs, 18 (72%) of 25 ulcers, and 8 (61.5%) of 13 limbs, respectively. Conclusion-Intramuscular injection of naked HGF plasmid is safe and feasible and can achieve successful improvement of ischemic limbs as sole therapy. (Arterioscler Thromb Vasc Biol. 2011;31:713-720.)
R ecent progress in molecular biology has led to the development of gene therapy using intramuscular transfection of genes encoding angiogenic cytokines as a potential new strategy to treat patients with peripheral arterial disease (PAD) or myocardial ischemia. Although beneficial effects of therapeutic angiogenesis using vascular endothelial growth factor (VEGF) gene transfer have been reported in clinical trials, [1] [2] [3] [4] some recent reports [1] [2] [3] 5 have documented disadvantages of VEGF, such as the development of leg edema. Placebo-controlled studies 6 -8 failed to show efficacy. In addition, some recent trials 9 using fibroblast growth factor 4 did not show improvement of clinical end points. Thus, it is important to examine the feasibility of other angiogenic growth factors. From this view point, we focused on hepatocyte growth factor (HGF) because it is a potent angiogenic growth factor in mouse, rat, and rabbit ischemia models, including high-risk conditions such as diabetes mellitus and high lipoprotein(a) concentrations. 10 -16 More important, the mitogenic activity of HGF might be more potent than that of VEGF, without edema formation. 11, 17 Based on previous data, we designed a human clinical trial of gene therapy for PAD using the HGF gene as an open-labeled phase I/IIa study. The primary objective of this study was to evaluate the safety and feasibility of intramuscular injection of plasmid HGF in patients with critical limb ischemia. The secondary objective was to assess its potential therapeutic benefit.
Methods

Plasmid DNA
A 3.0-kb plasmid vector (pVAX1), commercially produced by Invitrogen Corporation, was selected for the HGF construct because it incorporates elements in compliance with the Food and Drug Administration. 18 To minimize the possibility of chromosomal integration, insertional mutagenesis through the activation of oncogenes or the inactivation of tumor suppressor genes (all sequences with possible homology to the human genome) have been removed from the pVAX1 DNA, along with any sequences not necessary for replication in Escherichia coli or for expression of recombinant protein in mammalian cells. The pVAX1-HGF plasmid consists of a cDNA fragment of human HGF (EcoRI/NotI, 2.2 kbp) inserted into the pVAX1 vector. The construct does not have DNA sequence homology to the human genome (except the HGF insert), and the vector sequences do not have known oncogenic potential.
Patient Cohort
In this initial single-center, prospective, open-label study, patients could be enrolled as follows: (1) if they had chronic critical limb ischemia, including rest pain and/or a nonhealing ischemic ulcer, for a minimum of 4 weeks; (2) if they had been resistant to conventional drug therapy for Ͼ4 weeks (before enrollment); (3) if they were not candidates for surgical or percutaneous revascularization based on usual standards of practice; (4) if they did not have previous or current neoplasms; and (5) if they did not have severe retinopathy, as previously documented. 19 Objective documentation of ischemia, including a resting ankle-brachial index (ABI) of Ͻ0.6 in the affected limb on 2 consecutive examinations performed 1 week apart, was necessary. Patients were observed for 4 weeks under conventional drug therapy to confirm that their clinical symptoms and objective parameters were not improved. After confirmation of the selection criteria by an independent committee for assessment and evaluation of clinical gene therapy at Osaka University, Suita, Japan, which was approved by the Ministry of Health, Labor and Welfare and the Ministry of Education, Culture, Sports, Science and Technology, 22 limbs of 17 patients (13 men and 4 women; meanϮSD age, 59.6Ϯ12.0 years) with arteriosclerosis obliterans (PAD) (nϭ14) or Buerger disease (nϭ8), staged as Fontaine IIb, III, or IV, underwent direct intramuscular gene transfer of naked plasmid DNA encoding HGF. The characteristics of the patients are shown in supplemental Table I (available online at http://atvb.ahajournals.org). In 4 patients, plasmid was administered to bilateral legs one by one at an interval of Ͼ3 months. One patient was treated bilaterally at the same time.
Intramuscular Injection of Naked Plasmid DNA Encoding Human HGF
Each patient received an intramuscular injection of naked plasmid DNA encoding the HGF gene, regulated by the cytomegalovirus promoter/enhancer. Preparation and purification of the plasmid from cultures of HGF-transformed E coli were performed at Qiagen, Inc, using kanamycin. The purified plasmid was transported to the human gene therapy laboratory at Osaka University Medical School and stored in vials at Ϫ20°C. Some of them were pooled for quality control analysis and sequence checking. No vectors were used for plasmid delivery.
This study was divided into 2 stages. In the first stage, for the initial 6 patients with Fontaine stage III or IV, a test intramuscular injection of a small dose (0.4-mg plasmid DNA) was performed to examine acute or subacute allergy to plasmid DNA. After confirmation of no allergic reaction or anaphylaxis, a therapeutic dose (2 mg) of naked HGF plasmid DNA was intramuscularly injected 2 weeks after the test injection. The HGF plasmid DNA (0.5 mg) was diluted in sterile saline solution Յ3 mL, and 4 aliquots (total, 2 mg/12 mL) were administered into the calf or distal thigh muscles of the ischemic limb by direct intramuscular injection under ultrasonic guidance. Four injection sites were selected arbitrarily, according to the angiographic findings and the available muscle mass. The injection sites were described in a previous preliminary report. 18 Four weeks after the initial injection, a second injection (2 mg) was similarly administered, giving a total dose of 4-mg plasmid DNA per patient. The preliminary results of stage 1 were previously published. 18 In the second stage, 16 limbs of 12 patients with Fontaine stage IIb, III, or IV were intramuscularly injected with a therapeutic dose (2 mg/4 sites or 4 mg/8 sites) of naked HGF plasmid DNA. The doses of HGF plasmid were randomly allocated using an envelope method. The HGF plasmid DNA (0.5 mg) was diluted in sterile saline solution Յ3 mL, and 4 or 8 aliquots (total, 2 or 4 mg/12 or 24 mL) were administered into the calf or distal thigh muscles of the ischemic limb by direct intramuscular injection under echosonographic guidance. A total of 4 or 8 injection sites were selected arbitrarily, according to the angiographic findings and the available muscle mass. The injection sites of plasmid DNA are described in a previous preliminary report. 18 Four weeks after the initial injection, a second injection was similarly administered, giving a total dose of 4-to 8-mg plasmid DNA per patient.
Patient Follow-up and Assessment
Safety Assessment
Safety was assessed by evaluation of adverse events; concomitant medication use; vital signs; physical examination, hematology, blood chemistry, coagulation, urinalysis, chest X-ray, and electrocardiographic findings; and cancer and retinopathy screening. In addition, assays for HGF protein in serum and HGF plasmid in blood were performed. The serum HGF protein level was analyzed using an ELISA 20,21 at baseline and weekly for Յ12 weeks after the initial treatment. The blood level of plasmid DNA was measured using a real-time PCR method. 22
Efficacy Assessment
The initial efficacy end point was an increase in ABI by Ն0.1, a reduction in ulcer size (long axis) by Ն25%, and a reduction in visual analog scale (VAS) score by Ն2 cm at 2 months after the second injection of the HGF gene. Patients were observed. The status of PAD was evaluated by a physical examination that included change in ischemic ulcers, rest pain analysis using the VAS, measurements of ABI and toe-brachial pressure index, and transcutaneous (Tc) PO 2 weekly during the first 12 weeks, every other week for the next 8 weeks, monthly for the next 12 weeks, and then every 3 months for Յ2 years after the first injection of plasmid DNA, as described in a previous report. 19 All patients received usual full-drug therapy for PAD, including antiplatelet drugs, which were not changed throughout this trial. Ischemic ulcers and necrotic lesions were managed in a standard fashion. No patients with Fontaine IIb participated in a supervised exercise training program during the study. The ABI was measured using the toe plethysmographic wave or the Doppler wave system, IMEX (GETS Brothers). Intra-arterial digital subtraction angiography, magnetic resonance angiography, and, if possible, computed tomographic angiography were performed within 1 month before the first injection, 4 weeks after each treatment, and 3 months after the final intramuscular injection. Rest pain was evaluated objectively using a 10-cm VAS.
Statistical Analysis
All values are expressed as meanϮSD. For comparison of differences in the means of continuous parametric measurements between baseline and after gene therapy, a Student paired t test was used. For comparison of nonparametric values, such as VAS score, a Wilcoxon signed-rank test was used. To identify the prognostic background factors associated with end points, we evaluated the difference of change in ABI, ulcer size, and VAS score between the groups. Changes in ABI and ulcer size were assessed with the Student t test, whereas change in VAS score was assessed with the Mann-Whitney U test. PϽ0.05 was considered statistically significant. All tests were 2-tailed. To avoid any bias, an evaluation committee independent from the trial investigators checked all the data.
Results
A total of 22 limbs were treated with HGF gene transfer. Within 6 months after the second injection, 2 patients discontinued the study. Patient 3 withdrew consent at 82 days, and patient 4 discontinued the study at 140 days because of participation in another clinical trial of therapeutic angiogenesis using cell transplantation. There were no major amputations or deaths within 6 months.
The primary objective of this study was safety assessment. In particular, we focused on the incidence of angiogenesisrelated disease, such as tumors, and other severe complications. The initial preliminary trial documented no evidence of an allergic reaction related to plasmid DNA. 19 Similarly, none of the injections of human HGF plasmid DNA induced an allergic or anaphylactic reaction. During 6 months of followup, no serious adverse events related to gene therapy were seen (Table 1 and supplemental Table II ). Although 17 patients showed serious adverse events, the committee evaluated these incidents as not related to gene therapy. None of the patients showed leg edema, although transient lowerextremity edema had been reported with clinical gene therapy using the VEGF gene because of an increase in vascular permeability. The development of neoplasms or the progression of diabetic retinopathy has not been observed in any patient during the trial. Two-month follow-up angiographic studies showed no evidence of development of hemangioma. In addition, we evaluated the pharmacokinetics of the HGF gene. No significant increase in serum HGF protein concentration was observed throughout the gene therapy periods ( Figure 1A) . The blood level of plasmid HGF DNA decreased to less than detection limits 1 week after transfection, whereas a low level of plasmid DNA could be detected 1 day after treatment ( Figure 1B ).
Hemodynamic Assessment
It is difficult to detect distinct angiogenesis because angiography cannot visualize vessels Ͻ200 m; we evaluated the change in ABI as a hemodynamic end point. In patients with critical limb ischemia (CLI) (Fontaine III and IV), the ABI significantly increased from 0.44Ϯ0.08 at baseline to 0.59Ϯ0.14 at 2 months after the second injection (PϽ0.001 versus baseline) and to 0.65Ϯ0.18 at 6 months (Pϭ0.002 versus baseline) (Table 2 and Figure 2A ). Moreover, in combination with the Fontaine IIb group, the ABI significantly improved at 2 and 6 months ( Table 2 and Figure 2B ). Improved ratios of ABI in individual patient groups were 1.32 (95% CI, 1.17 to 1.42; PϽ0.001 versus baseline) at 2 months and 1.49 (95% CI, 1.23 to 1.80; PϽ0.001 versus baseline) at 6 months in patients with Fontaine III and IV; and 1.29 (95% CI, 1.18 to 1.40; PϽ0.001) at 2 months and 1.43 (95% CI, 1.25 to 1.63; PϽ0.001) at 6 months in patients with Fontaine IIb, III, and IV. According to the standard of Rutherford and Becker, 23 we defined an increase in ABI of Ͼ0.1 as a clinically meaningful improvement. At 2 months after injection, 11 (64.7%) of 17 limbs showed a positive response ( Table 3 ). The toe-brachial pressure index was increased at both 2 and 6 months in patients with Fontaine IIb through IV, whereas no significant change was observed in the Fontaine III and IV groups (Figure 2A 
Rest Pain and Ulcer
We evaluated changes in rest pain and ischemic ulcer size to assess the effects of HGF gene therapy on clinical symptoms and signs of PAD. We evaluated rest pain using a VAS as a standard method for the evaluation of pain, where 0 cm means pain free or no pain; and 10 cm, the most severe pain. As shown in Table 2 and Figure 2C , rest pain was significantly improved. The VAS score significantly decreased from 5.92Ϯ1.67 to 3.04Ϯ2.50 (Pϭ0.001 versus baseline) at 2 months after gene transfer. This improvement was sustained at 6 months. Of 13 patients, 8 (61.5%) demonstrated an improvement of Ͼ2 cm (Table 3) . Initially, 25 ischemic ulcers were found in 11 limbs. At 2 months after the second injection, the size of all the ischemic ulcers significantly reduced from 2.32Ϯ1.37 to 1.47Ϯ1.61 cm (PϽ0.001 versus baseline; nϭ25), and the size of the largest ulcers in each patient also significantly decreased from 3.08Ϯ1.54 to 2.32Ϯ1.88 cm (Pϭ0.007 versus baseline; nϭ11) at 8 weeks after injection ( Table 2 and Figure 2D ). Considering a reduction in ulcer diameter (long axis) of Ͼ25% as positive, †Cerebral infarction was induced by the catheter procedure. 
Maximum Walking Distance
In this trial, 7 patients with Fontaine IIb were also examined. PϽ0.001 versus baseline) (supplemental Figure II) . Of 7 limbs, 5 (71.4%) showed an improvement in maximum walking distance by Ͼ50% (Table 3 ).
Dose-Dependant Effect and Background Factor on Efficacy
In addition, we analyzed the dose-dependent effects of HGF gene therapy. As shown in Table 4 , the present study showed no significant difference in the improvement in ABI and clinical symptoms between the 2-and 4-mg groups. However, in the clinical trial, 4 mg per injection (total, 8 injection sites) seemed to be better because it is easy to define the injection points from the angiogram. In addition, we also evaluated the effects of risk factors linked to atherosclerosis, such as diabetes. Unexpectedly, as shown in Table 4 , none of the risk factors affected the efficacy of HGF gene therapy. Lesions limited to the lower thigh showed a tendency toward improvement in ABI (Pϭ0.08). We also evaluated the efficacy in patients with PAD and Buerger disease separately. Both patient groups showed an improvement in ABI and clinical symptoms (Table 4) , with no significant difference in the effects on rest pain or ulcer size between the 2 groups.
Discussion
The present study evaluated the safety and feasibility of HGF gene therapy in all 22 limbs after the initial preliminary report of data from 6 limbs. 19 Major new findings based on data from the completed study involving 22 limbs were that the present study demonstrated the safety of HGF gene therapy and improvements in ABI, VAS score, and ulcer size during a follow-up of 6 months (2 months previously). Moreover, the present study documented that the beneficial results of HGF gene therapy were sustained during the 6 months of follow-up. The natural history of critical limb ischemia has been well documented to have an inexorable downhill course. 24, 25 The inclusion criteria for this study were drafted to restrict treatment to patients in whom the natural history of critical limb ischemia was previously established. In particular, this trial excluded patients who demonstrated an improvement of clinical symptoms after hospitalization and pharmacological treatment to identify the effects of HGF gene therapy on clinical symptoms, although this trial was an open-label study. Efficacy and safety were evaluated by a committee independent and separated from the investigators. Although the inclusion criteria required a minimum of 4 weeks of conservative measures without evidence of improvement, in reality, signs and/or symptoms of critical limb ischemia were present in all patients for 2 to 10 months before enrollment.
In the current study, there was no major amputation or death up to 6 months of follow-up. Because this trial did not involve a placebo group, we cited the historical control arms from randomized medical therapy trials as the natural history of nonrevascularized CLI. A randomized trial of patients with CLI, with or without a prostaglandin E1 analog, revealed that the 6-month death rate and the major amputation rate were 10.2% and 16.2% in the prostaglandin E1 group (nϭ179) and 5.6% and 13.0% in the placebo group (nϭ177), respectively. 26 These results suggest that HGF gene therapy provides a favorable outcome compared with natural history.
As surrogate end points, we used ABI, rest pain assessed by VAS, and the size of ischemic ulcers because the evaluation with angiograms is questionable as quantification analysis for local angiogenesis. Several efficacy parameters were improved between the first and second injection, such as ABI in patients with CLI, ABI and toe-brachial pressure index in patients with Fontaine IIb through IV, all ulcers, and rest pain (Figure 2A through 2D ), suggesting that HGF gene therapy began to exert its effect early after the first injection. The absolute ankle pressure was significantly increased in 11 limbs after gene therapy. The ABI increased from 0.46 at baseline to 0.59 at 8 weeks after the second injection. To place this in perspective, an increase in ABI of Ͼ0.1 is considered as an index of a successful surgical or percutane-ous intervention. 23 To our knowledge, such an improvement has not previously been achieved spontaneously or with medical therapy in patients with critical limb ischemia. Rest pain, as assessed by VAS score, was significantly improved from baseline to 2 months. Ischemic ulcers healed or improved markedly by Ͼ25% in 7 of 11 limbs. Given the poor prognosis for patients with chronic critical limb ischemia, in whom the possibility of spontaneous improvement is remote, 27 the outcome in this cohort is encouraging. Moreover, these benefits in ABI, VAS score, and ulcer size were sustained until 6 months. Nevertheless, the present study did not fully eliminate placebo effects because it was not randomized, placebo controlled, or double blinded. This is a study limitation. To overcome this limitation, 2 randomized, placebo-controlled, double-blind studies (a phase III trial in Japan and a phase II trial in the United States) were performed to confirm the effectiveness of HGF gene therapy. The multicenter, double-blind, placebo-controlled phase II clinical trial 28 of HGF gene therapy demonstrated a significant increase in Tc PO 2 in the high-dose HGF group compared with the placebo group. The Japanese study showed a significant benefit in the response rate (rest pain and ulcer size reductions) in the HGF plasmid group compared with the placebo group. The differences between the phase II US trial and the present study are as follows: (1) the patient population (PAD versus PAD plus Buerger disease), (2) the injected sites (predefined versus disease-dependent sites), and (3) a randomized versus an open-label study. In particular, the difference in the results of the Tc PO 2 measurement might be because of the difference in the injection sites of HGF plasmid DNA between the Japan and US study. In the Japan study, the injection sites were defined by the analysis of a computed tomogram or an angiogram. Therefore, in some patients in the Japan study, the injection sites were only limited to the foot. It might be easy to understand that these patients would not change Tc PO 2 because the angiogenesis might be limited in the closed area. In contrast, in the US study, the sites were predefined at 4 sites below the knee and at 4 sites above the knee. Thus, a possible explanation of the difference between the Japan and US study might be the injection sites. We analyzed the effects of background factors on the efficacy of HGF gene therapy. Unexpectedly, no risk factors, such as diabetes or hypertension, appeared to affect efficacy. Interestingly, lesions limited to the lower thigh tended toward improvement in ABI. This difference might be related to the size of blood vessels or the degree of collateral formation. Alternatively, this phenomenon could provide criteria to decide the indication for either therapeutic angiogenesis or classic vascular bypass, although further studies are necessary. Moreover, there were no statistically significant differ-ences in their background between 4 nonresponders and 18 responders. The reasons for these results might be that there were not enough patients or limbs to make the comparison or that there was confusion over the pathological status. These are the major limitations of the study. In addition, there was no significant difference in the benefit seen from HGF gene therapy between the patients with PAD due to atherosclerosis and Buerger disease. However, in patients with critical limb ischemia (Fontaine III and IV), nonresponders were seen in 28.6% (2/7) of Buerger limbs in contrast to 0% (0/8) of atherosclerotic PAD limbs. This was different from the result of the angiogenic cell therapy study 29, 30 in which patients with Buerger disease showed greater improvement in limb salvage than those with PAD. Possible explanations for the difference between HGF study and cell therapy are as follows. (1) In general, Buerger disease involves a recurring, worsening, and remission phase, whereas PAD due to atherosclerosis has a relatively chronic and stable course. In the current study, the 2 nonresponders might have been in the Buerger active phase. (2) Baseline ulcer sizes of Buerger were 1.8 cm 2 (nϭ28) in the cell therapy group 29 in the long axis (9.1 cm 2 , nϭ5) in the HGF gene therapy group, suggesting that the Buerger group patients enrolled in the HGF study were more refractory than those in the cell therapy group. (3) Because the number of injection sites is also different between cell therapy (nϭ40 sites) and HGF therapy (nϭ4 or 8 sites), cell therapy might have been more effective for large ischemic lesions. These contrasting results from cell and HGF therapy may suggest that the cell therapy protocol is suitable for patients with Fontaine III and IV Buerger disease than HGF gene therapy. However, because of the difference of the criteria of efficacy between cell therapy (amputation and/or death) and HGF gene therapy (VAS or ulcer size), these results could not be compared directly. To elucidate an effect of background factor and difference between cell therapy and HGF gene therapy, a further study enrolling many patients is required.
Regarding the safety issue, 355 adverse events were reported at 2 months and 637 adverse events were reported at 6 months. At 6 months, 24.0% of adverse events, most of which are moderate or mild (eg, pain at the injected sites or small hematomas), were considered to relate to gene therapy (supplemental Table IIIA and IIIB). In 1 patient, a cerebral infarction occurred after the catheter procedure in angiography. This serious adverse event was considered to relate with the study protocol, not the study drug. Other serious events were excluded from being related to gene therapy. Potential adverse effects, such as hemangioma, cancer, or worsening of diabetic retinopathy, were not observed up to 6 months after the second transfection. Nevertheless, these findings are preliminary and do not establish the long-term safety of HGF. Different from previous reports of VEGF gene therapy, in which the VEGF protein level showed a transient peak in the systemic circulation 1 to 3 weeks after gene transfer, our trial did not demonstrate an increase in serum HGF concentration during gene therapy. Neoplasm or diabetic retinopathy might not be induced by HGF gene therapy because these complications would have to be due to an increase in plasma HGF secreted from transfected cells. These risks related to HGF gene therapy would be minimized by using injection of naked plasmid DNA into muscle. Although the present study demonstrated no increase in serum HGF concentration during gene therapy, the circulating level of HGF is elevated in patients with hypertension, PAD, and myocardial infarction. [31] [32] [33] There was no evidence of edema in the patients transfected with the human HGF gene, in marked contrast to a phase I/IIa VEGF trial in which 60% of patients developed moderate or severe edema. The difference between HGF and VEGF might be mediated by different actions on the migration of vascular smooth muscle cells. 34 Overall, the present phase I/IIa open-label study demonstrated that intramuscular injection of naked HGF plasmid is safe and feasible and might achieve successful improvement of ischemic limbs as sole therapy.
